Amotosalen and Platelet Transfusion in Pediatric Heart Surgery
NCT05128084 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2021-11-19
Summary
High level of security during blood transfusion has been achieved by donor selection and pathogen detection using serology or direct identification. Nevertheless, blood banking becomes hazardous during epidemic outbreaks or facing new pathogens. Amotosalen, a psoralen, targets nucleic acids and destroys them after ultraviolet exposure, resulting in inactivation of pathogens.
Treatment inoccuity and efficacy have been demonstrated but preservation of platelet functions after treatment is still debated. Previous studies focused on hematological patients. There is no evidence for an increased requirement of transfused platelets to achieve platelet count target. Studies in heart surgery are lacking.
The investigators perform a multicenter, retrospective, "before/after", controlled study in minor patients requiring heart surgery with cardiopulmonary bypass. One center (Strasbourg) uses Amotosalen-treated platelet concentrates since 2006 (control arm). This treatment becomes available in Bordeaux in October 2017 (intervention arm). There is two periods of inclusion: one "before" (January 2016 to June 2017) and one "after" (January 2018 to June 2019).
Conditions
- Congenital Heart Disease in Children
Sponsors & Collaborators
-
University Hospital, Strasbourg, France
lead OTHER
Principal Investigators
-
Xavier DELABRANCHE, MD · Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg
Eligibility
- Min Age
- 1 Year
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-01
- Primary Completion
- 2021-12-31
- Completion
- 2021-12-31
Countries
- France
Study Locations
More Related Trials
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
NCT02604433 ·Status: COMPLETED ·Phase: PHASE3
-
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
NCT06358638 ·Status: RECRUITING ·Phase: PHASE2
-
The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation
NCT00789516 ·Status: COMPLETED
-
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
NCT05577312 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients
NCT05255445 ·Status: COMPLETED
-
Haploidentical PBMC Transplant for Severe Congenital Anemias
NCT00977691 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
NCT01005576 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
NCT07338344 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
NCT05773729 ·Status: RECRUITING ·Phase: NA
-
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
NCT06302491 ·Status: RECRUITING ·Phase: PHASE2
-
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
NCT06364774 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.
NCT05860595 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
NCT02126046 ·Status: UNKNOWN ·Phase: NA
-
Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
NCT01206075 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
NCT06219239 ·Status: RECRUITING ·Phase: NA
-
A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
NCT06772766 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
NCT05036512 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
NCT02342145 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major
NCT00336362 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
NCT01740531 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
NCT02151526 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
NCT01745120 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study
NCT05462548 ·Status: UNKNOWN ·Phase: PHASE4
-
Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery
NCT07027670 ·Status: COMPLETED ·Phase: PHASE2
-
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
NCT00061568 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2